A doctor at New York's Weill Cornell Medical College has defended U.S. drug spending, which accounts for 42 percent of drug sale money worldwide.
Dr. Marcus Reidenberg said he does not see a problem with the high amounts of pharmaceutical consumption, which exceeded $250 billion in 2005, provided patients are properly educated, CBS News reported Monday.
"If the individual is troubled enough by the problem, knows what the risks are of the medicine, (including the fact that these new medicines -- we don't know what all the risks are), and still feels that the benefit is worthwhile -- I don't have a problem with it," Reidenberg told CBS.
However, critics of the industry have said they are concerned that people are taking drugs they do not need after seeing them advertised on television.
"There is no drug trial in the world where anyone is taking five drugs simultaneously and they are looking at the interactions. So why is it a bad idea? I don't want to be part of some experiment," New York University clinical psychologist Leonore Tiefer said to CBS News.
Copyright 2006 by United Press International
Related stories:
Hybrid Nanoparticles Image and Treat Tumors
(PhysOrg.com) -- By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.
Researcher Finds New Method to Create Cancer Drugs
When fixing a car, it’s a good idea to have more than one type of wrench. Similarly, when doctors treat cancer patients, they like to have different “tools” available. Cancer tumors can be big or small. Some tumors grow very fast, while others grow slowly. Now, a University of Missouri researcher has developed a method that would make it easier for doctors to pick and choose different radiopharmaceuticals to treat different types and sizes of cancer and tumors.
Scientists race to stay ahead of the drug-taking and genetic manipulation that threatens sport
The race to ensure that scientists stop drug-taking athletes from damaging sport by using performance enhancing drugs or undergoing genetic manipulation is a constant challenge, according to a major four-decade review by three of the World's leading experts on doping in sport.
Probing Question: Fishhooks of addiction
When the American writer Theodore Roethke taught at Penn State from 1936 to 1943, he was known for three things: being a good poet, coaching the men’s tennis team, and falling down drunk, perhaps the latter more than the former. Roethke, a brilliant and tortured man, knew well the seduction of drink and the agony of addiction. In his poem “Journey Into the Interior,” Roethke writes, “In the long journey out of the self, / There are many detours, washed-out interrupted raw places / Where the shale slides dangerously / And the back wheels hang almost over the edge / At the sudden veering, the moment of turning.”
Researchers identify potential new drug candidates to combat 'bird flu'
As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.
Salutary pizza spice
Oregano doesn´t only give a Pizza its typical taste. Researchers at Bonn University and the ETH Zürich have discovered that this spice also contains a substance which, amongst other qualities, appears to help cure inflammations. The researchers administered its active ingredient – known as beta-caryophyllin (E-BCP) - to mice with inflamed paws. In seven out of ten cases there was a subsequent improvement in the symptoms. E-BCP might possibly be of use against disorders such as osteoporosis and arteriosclerosis. The study has appeared on Monday, 23rd June in the
Proceedings of the National Academy of Sciences (PNAS).
Duke chemist has new way to tell right from left
A Duke University chemist has apparently solved a long-standing frustration in creating certain synthetic molecules that make up drugs, which could lead to better drugs with fewer side effects.
Treating safety research like other clinical studies slows progress
Progress in patient safety research could slow to a crawl unless regulators work out a host of ethical issues, Johns Hopkins researchers assert in an upcoming opinion piece.